You stated it correctly, dilution is not eminent, not my thought at all, merely reading between the lines of Vater's comments to the questions posed by Yi Chen, when he answered as to "sufficient cash to complete the INTUS trial" he said they would take another look in (early?) 2016 provided there is "nothing external".
The PCT revenues they played up, growth of 31% over 2Q '14, check out the 10Q to see what the cost of those revenues were, and you will see this company is a long long ways from generating any money through PCT. Also note their OXFORD long term debt they just rescheduled out to April 2016 before they have to begin paying back principal and interest. That was in the 10-K for December 31, 2014. This will pay back over the next three years, $19.2M. It's a long wait and there will be additional dilution with their new $150MM shelf offering.
I am listening to the CC again now, looking for nuggets. They are cutting out burn by not pursuing further development after Preserve. Their growth of PCT revenues at the 31% growth rate they announced Q over Q, then the revenue for 2016 could approach $31.5M. Their burn rate historically has been between 18-47M but for 2015 is closer to 32M, so even with the CIRM and other grants ($20M) they are going in the right direction. I will need to spend more time with this to give a better overview. For now I am holding.
$55 to go, this break reminds me of the July swoon over the exclusions by the PBM's. With both biotech and momentum stocks being hit today, there was a very soft spot in our armour, exasperated by the mutual lawsuits over the DEPO merger. All this will clear in time, and we'll be back to business. Tomorrow's call may bring a reset to the stock, in which case today's breakdown is an excellent buying opportunity for those holders who aren't over-extended or fully invested.
Sentiment: Strong Buy
Good day, my position was nearing $1.00 oversold but today brings me within .25 of breaking even, so was worth it holding through the uncertainty and downdraft. Now a lot of longs here can get back some of their money, I agree new eyes will swing to this trade, hopefully we'll see a better broad market tomorrow and follow through here to the upside.
Sentiment: Strong Buy
July 30, 2015
New York, July 30, 2015 — Caladrius Biosciences, Inc. (“Caladrius”) (NASDAQ:CLBS), a cell therapy leader with a Phase 3 clinical program in immuno-oncology and a portfolio of projects in immune modulation and regenerative medicine, announced today that it will report its financial results for the second quarter ended June 30, 2015 on Thursday, August 6, 2015. Dr. David J. Mazzo, Chief Executive Officer, and Robert S. Vaters, President and Chief Financial Officer, will discuss results and provide a company update via a webcast and conference call on Thursday, August 6, 2015 at 4:30 pm ET.
To access the webcast, visit the Investor Relations section of the company’s website at http://www.caladrius.com/investors/overview/. Alternatively, callers may participate in the conference cell by dialing 877-562-4460 or, for international callers, 513-438-4106, and providing conference ID 95197846. Please note that the earlier conference ID provided was incorrect.
An archive of the webcast will be available approximately two hours after the completion of the call. To access the archived webcast, visit http://www.caladrius.com/investors/news-events/events/.
Good call, I didn't want this to happen but the Market speaks volumes. Did you cover your short, or are you long and just out of funds to buy more?
Wow, and I thought IDRA and TROV were rough seas! TROV hit it's 250 day moving average today and I'll bet that's all. IDRA who knows, it looks low but we'll have to wait and see, don't have any feel for SUNE, hope he doesn't have size in that one. Good luck holding all these MGM, hope you're not on margin.
Yes, very tough--emotionally it's opposite, but I did manage to add 3,000 shares today, in three lots, the lowest being 3.02, 3.08, and ugh...3.27. for a 3.12 average. Now holding a total of 98K in four accounts, at $3.31/sh. I remain cautiously optimistic on price targets for this year. Somewhere between 5.50 and $7.50.
Jackie, I don't see that funds are desperate, really? This accumulation has been going on for quite some time and they are averaging in, do you really believe funds are desperate? Let's not overstate it, too many here have done that already.
It's nervous time adding after such a steep rise, but you'll be smart looking back a couple months from now. I did add myself this morning, good luck.
Lefty, don't beat yourself up, you have plenty of other folks here who have lost most of their invested equity dollars and many continue to hold but just don't post. We haven't lost, we are being shaken. There are plenty of reasons why investors flocked to this company in the last 6 months and are now staring at major deep red like us. I have to believe that all the good we saw wasn't a mirage, but actually the seeds of success that will eventually bear fruit and cause this Company to win in the long run. What do you think CIRM is feeling now that their recipient company has been flogged by the market since this was announced? They put up $17.7M! It was a major endorsement, they study this stuff every day, so my money was first endorsed by their money.
Price targets for EOY have ranged from $5's to $15. Mid range and most repeated seem to be $7 up to $10. That's a far fling from where we are now and how the stock has(n't) performed. I agree with your pulling back on the expectations, the majority of large hands here have been overly optimistic by raising expectations to unrealistic levels. I don't think we'll be over $5.50, hope the others are right and I am wrong.
Your noodling on HZNP runs deep and long like the Colorado River. Your insights have been extremely valuable to the YMB, glad you decided to stay involved. This be but a blip on our journey!
7:24 am Synta Pharma reports Q2 EPS of ($0.15) vs ($0.19) estimate with no revs; Phase 3 GALAXY-2 trial on track for interim analysis by year end 2015 (SNTA) : As of June 30, 2015, the Company had $98.3 million in cash, cash equivalents and marketable securities, compared to $97.7 million in cash, cash equivalents and marketable securities as of December 31, 2014.
Since I had rushed in ahead of the ER to add more shares, it was a 'bigger' rough day for me, but in the background I had AVXL ramping up my portfolio, so the rapid pain is soon forgotten. Hopefully people will take time to pour over the details presented in today's call and realize just how substantial and forward looking this management team is, they will take this short term blip and gather themselves for the many good years that lie just ahead.
stockpriker, do you feel better now? Why be such a prik? He's for sure the best poster on this site. Take a phrase as a show of confidence, not literally. Go fishing and cool off, quit puffing yourself up and trying to put others down.
It wasn't clear to me until these discussions taught me that we are at war with the institutions to keep our shares. I've always thought it was the shorts but didn't extend the identity to the institutions that we all want alongside us in guiding our investments. Of course, they just want us pushed aside like ants, away from their main course. It would be very interesting to see how the Baker Brothers actually conduct their day to day strategy in keeping retail investors at bay. Ranger, thanks for your part (prospern23 mainly) in getting me interested in AVXL. What a monster, nearly 300% already...congrats to you for going as large as you did!